Study on the intake and efficacy of nab-paclitaxel in patients with advanced cervical cancer

Cervical cancer is the second most common malignant tumor in women. This study aimed to investigate the intake and effect of nab-paclitaxel in chemotherapy for patients with advanced cervical cancer, to collect more evidence for clinical medication. A total of 96 patients with advanced cervical cancer who received chemotherapy treatment in Wuhan Third Hospital from July 2021 to July 2022 were randomly divided into observation group (treated with nab-paclitaxel + cisplatin) and control group (treated with paclitaxel + cisplatin) by envelope method. The short-term efficacy, tumor markers, immune function indicators, adverse reactions and quality of life of both groups were observed and compared with each other. After treatment, serum tumor markers were notably decreased, while cluster of differentiation 4 (CD4)+ and CD4+/cluster of differentiation 8 (CD8)+ were clearly increased in both groups. The observation group showed the improvement effect of each index in a statistically significant manner (p < 0.05) than the control group. The effective disease control rate of observation group was higher than that of the control group while the incidence of treatment-related adverse reactions in the observation group was higher than that of the control group. The observation group indicated improved effective rate of Karnofsky Performance Scale (KPS) than the control group (p < 0.05). In conclusion, nab-paclitaxel has significant advantages in chemotherapy for patients suffering from advanced cervical cancer, which can strengthen immune function, improve the effectiveness of disease control, and promote the improvement of functional status.

Nab-paclitaxel; Advanced stage; Cervical cancer; Application efficacy

[1] Tanigawa T, Takeshima N, Ishikawa H, Nishio S, Usami T, Yamawaki T, et al. Paclitaxel-carboplatin and bevacizumab combination with maintenance bevacizumab therapy for metastatic, recurrent, and persistent uterine cervical cancer: an open-label multicenter phase II trial (JGOG1079). Gynecologic Oncology. 2022; 165: 413–419.

[2] Ilhan Y, Tatli AM, Teker F, Onder AH, Kose F, Geredeli C, et al. Cisplatin plus paclitaxel and bevacizumab versus carboplatin plus paclitaxel and bevacizumab for the first-line treatment of metastatic or recurrent cervical cancer. International Journal of Gynecologic Cancer. 2022; 32: 502–507.

[3] Wang Y, Shen F, Zhou J, Fang Y, Qi Y, Chen Y. Overexpression of ARHI increases the sensitivity of cervical cancer cells to paclitaxel through inducing apoptosis and autophagy. Drug Development Research. 2022; 83: 142–149.

[4] DI MARTINO G, LISSONI AA, FERRARI D, DI MEO ML, COSIO S, GADDUCCI A, et al. Dose-dense neoadjuvant chemotherapy with paclitaxel and carboplatin in cervical cancer: efficacy on pathological response. Anticancer Research. 2021; 41: 497–502.

[5] Liu N, Zhang X, Chen J, Wang Q, Wu Q, Gao F, et al. Camrelizumab (SHR-1210) with carboplatin and albumin-binding paclitaxel in patients with metastatic or recurrent cervical cancer: an open-label, phase 2 trial. Journal of Cancer Research and Therapeutics. 2022; 18: 482.

[6] Li J, Liu H, Li Y, Li J, Shen L, Long W, et al. Comparison of outcomes and side effects for neoadjuvant chemotherapy with weekly cisplatin and paclitaxel followed by chemoradiation vs. chemoradiation alone in stage IIB–IVA cervical cancer: study protocol for a randomized controlled trial. Trials. 2022; 23: 29.

[7] ARAKAKI Y, ARIGA T, HEIANNA J, SHIMOJI Y, NAKASONE T, TAIRA Y, et al. Long-term outcomes of cervical adenocarcinoma treated with concurrent Chemoradiotherapy using paclitaxel and cisplatin. In Vivo. 2020; 34: 2739–2743.

[8] Della Corte L, Barra F, Foreste V, Giampaolino P, Evangelisti G, Ferrero S, et al. Advances in paclitaxel combinations for treating cervical cancer. Expert Opinion on Pharmacotherapy. 2020; 21: 663–677.

[9] Liu J, Zhang S, Yang F, Yin Y, Yu J, Cheng M, et al. Efficacy and safety evaluation of albumin-bound paclitaxel chemotherapy in East Asian patients with gynecological tumors based on the degree of paclitaxel binding to patient plasma. Anti-Cancer Drugs. 2022. [Preprint]

[10] Horiuchi M, Uemura T, Oguri T, Toda S, Yamamoto S, Suzuki Y, et al. Genetic variations in the ATP-binding cassette transporter ABCC10 are associated with neutropenia in Japanese patients with lung cancer treated with nanoparticle albumin-bound paclitaxel. Investigational New Drugs. 2022; 40: 934–943.

[11] Ma XH, Guo K, Dong WL, Jiang J. Efficacy and safety of paclitaxel liposomes compared to paclitaxel combined with platinum in concurrent chemoradiotherapy for unresectable cervical carcinoma: a meta-analysis. Chinese Journal of Oncology. 2021; 43: 1132–1139. (In Chinese)

[12] Ishikawa M, Shibata T, Iwata T, Nishio S, Takada T, Suzuki S, et al. A randomized phase II/III trial of conventional paclitaxel and carboplatin with or without bevacizumab versus dose-dense paclitaxel and carboplatin with or without bevacizumab, in stage IVB, recurrent, or persistent cervical carcinoma (JCOG1311): primary analysis. Gyne-cologic Oncology. 2021; 162: 292–298.

[13] Yasunaga M, Yahata H, Okugawa K, Shimokawa M, Maeda Y, Hori E, et al. Prognostic impact of adding bevacizumab to carboplatin and paclitaxel for recurrent, persistent, or metastatic cervical cancer. Taiwanese Journal of Obstetrics and Gynecology. 2022; 61: 818–822.

[14] Seber S, Sirin DY, Yetisyigit T, Bilgen T. Piperlongumine increases the apoptotic effect of doxorubicin and paclitaxel in a cervical cancer cell line. Nigerian Journal of Clinical Practice. 2020; 23: 386–391.

[15] Xiong J, Sheng J, Wei Y, Sun Z, Xiao X, Zhang L. Sesamol augments paclitaxel-induced apoptosis in human cervical cancer cell lines. Nutrition and Cancer. 2022; 74: 3692–3700.

[16] Nagao S, Yamamoto K, Oishi T, Yamaguchi S, Takehara K, Shimada M, et al. Phase II study of a new multidisciplinary therapy using once every 3 week carboplatin plus dose-dense weekly paclitaxel before and after radical hysterectomy for locally advanced cervical cancer. International Journal of Clinical Oncology. 2021; 26: 207–215.

[17] Zhao Y, Lan Y, Chi Y, Yang B, Ren C. Downregulation of Circ-CEP128 enhances the paclitaxel sensitivity of cervical cancer through regulating miR-432-5p/MCL1. Biochemical Genetics. 2022; 60: 2346–2363.

[18] Li XJ, You Y, Zhang QL, Zhang BB, Yan L, Ou ZM, et al. Preparation of paclitaxel-loaded and folic acid-modified poly (lactic-co-glycolic acid) nano-micelles and in vitro anticancer effect on cervical cancer HeLa cells. China Journal of Chinese Materia Medica. 2021; 46: 2481–2488. (In Chinese)

[19] Jianfang X, Ling Z, Yanan J, Yanliang G. The effect of Chaihu-shugan-san on cytotoxicity induction and PDGF gene expression in cervical cancer cell line HeLa in the presence of paclitaxel + cisplatin. Cellular and Molecular Biology. 2021; 67: 143–147.

[20] Redondo A, Colombo N, McCormack M, Dreosti L, Nogueira-Rodrigues A, Scambia G, et al. Primary results from CECILIA, a global single-arm phase II study evaluating bevacizumab, carboplatin and paclitaxel for advanced cervical cancer. Gynecologic Oncology. 2020; 159: 142–149.

[21] Chu G, Liu X, Yu W, Chen M, Dong L. Cisplatin plus paclitaxel chemotherapy with or without bevacizumab in postmenopausal women with previously untreated advanced cervical cancer: a retrospective study. BMC Cancer. 2021; 21: 133.

[22] Liu Y, Zhao R, Qin X, Mao X, Li Q, Fang S. Cobimetinib sensitizes cervical cancer to paclitaxel via suppressing paclitaxel-induced ERK activation. Pharmacology. 2022; 107: 398–405.

[23] Higami S, Tanaka Y, Deguchi T, Shiraishi M, Shiki Y. Acute ST-segment elevations following paclitaxel administration for uterine cervical cancer: a case report and literature review. Cardiooncology. 2022; 8: 22.

[24] Wang J. Combination treatment of cervical cancer using folate-decorated, pH-sensitive, carboplatin and paclitaxel co-loaded lipid-polymer hybrid nanoparticles. Drug Design, Development and Therapy. 2020; 14: 823–832.

[25] Li J, Li Y, Wang H, Shen L, Wang Q, Shao S, et al. Neoadjuvant chemotherapy with weekly cisplatin and paclitaxel followed by chemora-diation for locally advanced cervical cancer. BMC Cancer. 2023; 23: 51.

[26] Maene C, Salihi RR, Van Nieuwenhuysen E, Han SN, Concin N, Vergote I. Combination of weekly paclitaxel-carboplatin plus standard bevacizumab as neoadjuvant treatment in stage IB–IIB cervical cancer. International Journal of Gynecologic Cancer. 2021; 31: 824–828.

[27] Sun T, Zhang D, Wang Z, Zhao B, Li Y, Sun X, et al. Inhibition of the notch signaling pathway overcomes resistance of cervical cancer cells to paclitaxel through retardation of the epithelial-mesenchymal transition process. Environmental Toxicology. 2021; 36: 1758–1764.

[28] Li B, Xia X, Chen J, Xia D, Xu R, Zou X, et al. Paclitaxel-loaded lignin particle encapsulated into electrospun PVA/PVP composite nanofiber for effective cervical cancer cell inhibition. Nanotechnology. 2021; 32: 015101.

[29] Dong M, Li P, Xie Y, Wang Z, Wang R. CircMYBL2 regulates the resistance of cervical cancer cells to paclitaxel via miR-665-dependent regulation of EGFR. Drug Development Research. 2021; 82: 1193–1205.

[30] Pang K, Lee J, Kim J, Park J, Park Y, Hong E, et al. Degradation of DRAK1 by CUL3/SPOP E3 ubiquitin ligase promotes tumor growth of paclitaxel-resistant cervical cancer cells. Cell Death & Disease. 2022; 13: 169.